Additionally, a post hoc analysis of a phase 2 clinical trial of selonsertib, a selective ASK1 inhibitor, suggested selonsertib might be a potential therapeutic agent to prevent the progression of DKD despite the fact that the trail did not achieve the primary endpoint [79]. Here, MAP3K5 is linked to diabetic kidney disease.